AGV Discovery outlook

Pharmaceutical research within AGV Discovery focuses on the early development of targeted therapies in oncology. Established in 2013 on the basis of the research studies of Dr. Jean-François Guichou (CBS, INSERM, Montpellier), AGV Discovery team has identified and optimized series of small molecules active on therapeutic targets involved in the process of cancer development. The vision of AGV Discovery is to bring these research projects until pharmaceutical clinical development, in the aim to provide new therapeutic options for the treatment of cancers.


Today, two research programs are underway, a selective kinase inhibitor for the treatment of melanoma and colon cancer, and several combinations of inhibitors for the treatment of more aggressive cancers such as pancreatic and lung cancer. Pharmaceutical projects are the result of a intensive scientific collaboration between AGV Discovery and academic laboratories of Montpellier (INSERM, CNRS, University of Montpellier 1, University of Montpellier 2).


  • Décision d'agrément CIR2014-2016

    AGV Discovery a obtenu l'agrément "Crédit Impôt Recherche" pour les années 2014 à 2016....